Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
by: Mickaël Martin, Marion Sassier, Marion Allouchery, Thomas Lombard, Franck Rouby, Celia Bertin, Marina Atzenhoffer, Ghada Miremont-Salame, Marie-Christine Perault-Pochat, Mathieu Puyade
| Format: | Article |
|---|---|
| Published: | BMJ Publishing Group 2020-07-01 |
Tab content not available
Tab content not available
Tab content not available
Tab content not available
Tab content not available